Cargando…

Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients

In clinical trials and meta-analysis, atherosclerotic vascular events (AVEs) during treatment with immune-checkpoint inhibitors (ICIs) have been reported with low incidence. However, preclinical data suggest that these drugs can promote atherosclerosis inflammation and progression of atherosclerosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inno, Alessandro, Chiampan, Andrea, Lanzoni, Laura, Verzè, Matteo, Molon, Giulio, Gori, Stefania
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193098/ https://www.ncbi.nlm.nih.gov/pubmed/34124192 http://dx.doi.org/10.3389/fcvm.2021.652186

Ejemplares similares

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and the Heart
por: Mocan-Hognogi, Diana Larisa, et al.
Publicado: (2021)

Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
por: Quagliariello, Vincenzo, et al.
Publicado: (2022)

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
por: Quagliariello, Vincenzo, et al.
Publicado: (2023)

Inflammatory Mediators in Atherosclerotic Vascular Remodeling
por: Evans, Bryce R., et al.
Publicado: (2022)

Defective Protein Catabolism in Atherosclerotic Vascular Inflammation
por: Miyazaki, Takuro, et al.
Publicado: (2017)

Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022
por: Wu, Si, et al.
Publicado: (2022)

Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors
por: Chen, Ru, et al.
Publicado: (2021)

Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis
por: Zhang, Xin, et al.
Publicado: (2023)

Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes
por: Goldberg, Ronald B.
Publicado: (2020)

Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
por: Xu, Shirley, et al.
Publicado: (2021)

Gender Differences in Atherosclerotic Vascular Disease: From Lipids to Clinical Outcomes
por: Vakhtangadze, Tamar, et al.
Publicado: (2021)

Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series
por: Chye, Adrian M., et al.
Publicado: (2022)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022)

Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study
por: Zhang, Chuan, et al.
Publicado: (2023)

Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease
por: Decano, Julius L., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms
por: Rikhi, Rishi, et al.
Publicado: (2021)

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
por: Ganesh, Sridha, et al.
Publicado: (2022)

Perivascular adipose tissue in vascular pathologies—a novel therapeutic target for atherosclerotic disease?
por: Adachi, Yusuke, et al.
Publicado: (2023)

Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience
por: Xiao, Junjuan, et al.
Publicado: (2023)

Comprehensive Analysis of the Immune Infiltrates and Aberrant Pathways Activation in Atherosclerotic Plaque
por: Han, Hukui, et al.
Publicado: (2021)

PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
por: Quagliariello, Vincenzo, et al.
Publicado: (2023)

Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the heart of the issue
por: Gabbiadini, Roberto, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
por: Chen, Xue, et al.
Publicado: (2022)

A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer
por: Faubry, Clara, et al.
Publicado: (2022)

Retrospective angiographic study to determine the effect of atherosclerotic stenoses of upstream arteries on the degree of atherosclerosis in distal vascular territories
por: Rehwald, Rafael, et al.
Publicado: (2016)

Cardiac Complications in Immune Checkpoint Inhibition Therapy
por: Tajiri, Kazuko, et al.
Publicado: (2019)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
por: Ma, Minglu, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
por: Nakamura, Yoshiyuki
Publicado: (2019)

The relationship between Type D personality with atherosclerotic plaque and cardiovascular events: The mediation effect of inflammation and kynurenine/tryptophan metabolism
por: Wang, Yini, et al.
Publicado: (2022)

An Inhibitor of Grp94 Inhibits OxLDL-Induced Autophagy and Apoptosis in VECs and Stabilized Atherosclerotic Plaques
por: Wei, Qun, et al.
Publicado: (2021)

Higher risk of future events, mortality and greater healthcare use among patients with increasingly recurrent atherosclerotic cardiovascular disease events in Taiwan: a retrospective cohort study
por: Hsu, Chia-Yun, et al.
Publicado: (2023)

Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
por: Luo, Yue-Bei, et al.
Publicado: (2021)

Early detection of immune checkpoint inhibitor-related subclinical cardiotoxicity: A pilot study by using speckle tracking imaging and three-dimensional echocardiography
por: Xu, Aiqing, et al.
Publicado: (2022)

Artificial intelligence in atherosclerotic disease: Applications and trends
por: Kampaktsis, Polydoros N., et al.
Publicado: (2023)

Effects of norepinephrine on plaque hypoxia in atherosclerotic rabbits
por: Wang, Jia-Yu, et al.
Publicado: (2023)

Are acute type A aortic dissections atherosclerotic?
por: Grewal, Nimrat, et al.
Publicado: (2023)

Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
por: Scisciola, Lucia, et al.
Publicado: (2022)

Increased atherosclerotic plaque in AOC3 knock-out in ApoE(−/−) mice and characterization of AOC3 in atherosclerotic human coronary arteries
por: Filip, Anna, et al.
Publicado: (2022)

The Applications of Single-Cell RNA Sequencing in Atherosclerotic Disease
por: Slenders, Lotte, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8jkj22si83h5kkq59co23mbth0